Magnesium-28: A theorical novel self-theranostic strategy targeting metabolic enzyme disruption and intracellular irradiation

Abstract

The limitations of conventional cancer therapies, such as low selectivity and significant side effects, necessitate innovative approaches. This study proposes a pioneering self-theranostic strategy using magnesium-28 (Mg-28) alone, enabling simultaneous diagnosis, therapy, and treatment monitoring. Exploiting the elevated Mg ion demand in cancer cells, Mg-28 selectively targets Mg-dependent enzymes (e.g., DNA/RNA polymerases, hexokinase, telomerase) within intracellular organelles, such as the nucleus and mitochondria, without requiring biochemical carriers or nanoparticles, as in recent methods. A theoretical model based on the Mg-uptake coefficient predicts selective Mg-28 accumulation in tumors following intravenous administration. The Mg-28 decay chain—progressing through Aluminum-28 to stable Silicon-28—delivers highly localized irradiation through beta particles, Auger electrons, and recoil ions to critical intracellular structures, while simultaneously disrupting essential Mg-dependent enzymes. This results in a dual mechanism of radiotherapy and multi-enzyme inactivation. Simulations of linear energy transfer, radiation range, and absorbed dose show that nanogram-scale amounts of Mg-28 can deliver 60-400 Gy to tumors ranging from 0.03 mg to 500 g, suggesting potent cytotoxicity across a broad range of tumor sizes and stages. This potential is grounded in the universal metabolic reliance of cancer cells on Mg. Moreover, gamma emissions from Mg-28 and its daughter isotopes support early tumor detection and real-time treatment monitoring, enhancing therapeutic precision. As the first proposed single- isotope theranostic approach leveraging Mg dependency, this innovative strategy provides a robust foundation for future pre-clinical and clinical investigations aimed at validating its therapeutic efficacy, pharmacokinetics, and biosafety—thereby inaugurating a novel hypothesis for cancer therapy.

Keywords

Magnesium-28 / Intracellular irradiation / Multienzyme inactivation / Precision metabolic targeting / Self-theranostics / Magnesium uptake

References

[1] International Agency for Research on Cancer. Latest Global Cancer Data: Cancer Burden Rises to 19.3 Million New Cases and 10.0 Million Deaths in 2020. Available from: https://www.iarc.who.int/news-events/latest-global-cancer-data-cancer-burden-rises-to-19-3-million-new-cases-and-10-0-million-cancer-deaths-in-2020 [Last accessed on 2025 May 21].

[2] Baskar R, Lee KA, Yeo R, Yeoh KW. Cancer and radiation therapy: Current advances and future directions. Int J Med Sci. 2012; 9:193-199. doi: 10.7150/ijms.3635

[3] Fan D, Cao Y, Cao M, Wang Y, Cao Y, Gong T.Nanomedicine in cancer therapy. Sig Transduct Target Ther. 2023;8:293. doi: 10.1038/s41392-023-01536-y

[4] Zahavi D, Weiner L.Monoclonal antibodies in cancer therapy. Antibodies (Basel). 2020;9:34. doi: 10.3390/antib9030034

[5] Kalmouni M, Al-Hosani S, Magzoub M.Cancer targeting peptides. Cell Mol Life Sci. 2019;76:2171-2183. doi: 10.1007/s00018-019-03061-0

[6] Ratan ZA, Son YJ, Haidere MF, et al. CRISPR-Cas9: A promising genetic engineering approach in cancer research. Ther Adv Med Oncol. 2018;10. doi: 10.1177/1758834018755089

[7] Sterner RC, Sterner RM. CAR-T cell therapy: Current limitations and potential strategies. Blood Cancer J. 2021;11:69. doi: 10.1038/s41408-021-00459-7

[8] Lee S, Kim J. Advances in radioisotope applications for cancer diagnosis and treatment. J Nucl Med. 2019; 60:345-357. Krishnamurthy GT, Blahd WH. Radioiodine I-31 therapy in the management of thyroid cancer. A prospective study. Cancer. 1977; 40:195-202. doi: 10.1002/1097-0142(197707)40:1<195::AID-CNCR2820 400131>3.0.CO;2-C

[9] Krishnamurthy GT, Blahd WH. Radioiodine I-31 therapy in the management of thyroid cancer. A prospective study. Cancer. 1977;40:195-202. doi: 10.1002/1097-0142(197707)40:1<195::AID-CNCR2820 400131>3.0.CO;2-C

[10] Tran TVT, Rubino C, Allodji R, et al. Breast cancer risk among thyroid cancer survivors and the role of I-131 treatment. Br J Cancer. 2022;127:2118-2124. doi: 10.1038/s41416-022-01982-5

[11] Castiglioni S, Farruggia G, Cappadone C. Magnesium in Human Health and Disease. MDPI Books; 2021. Available from: https://www.mdpi.com/books/pdfview/book/4389 [Last accessed on 2025 May 21].

[12] Smith A, Jones B, Williams C. Utilization of magnesium-28 as a tracer in metabolic studies. J Metab Res. 2012;45:233-245.

[13] Brown R, Green P, Taylor M.Tracking magnesium uptake and distribution using Mg-28. BioMetals. 2016;29:163-178.

[14] Johnson L, Thompson D. Magnesium-28 in cellular metabolism: Insights and applications. Metab J. 2014;48:456-467.

[15] Tran VL, Hoang T. Nuclear transformation in metalloenzyme: A novel and high potential cancer treatment research. BioRxiv. 2023. doi: 10.1101/2023.08.10.552823

[16] Luyen VT. A proposal for a cancer treatment study involving radioactive metal co-factor enzymes. In: Highlights on Medicine and Medical Science. Vol. 15. West Bengal: BPI; 2021. p. 1-5. doi: 10.9734/bpi/hmms/v15/9276D

[17] National Nuclear Data Center.Mg-28 Beta Decay Data. Available from: https://www.nndc.bnl.gov/ensnds/28/Mg/beta_decay.pdf [Last accessed on 2025 May 21].

[18] Cowan JA. Structural and catalytic chemistry of magnesium- dependent enzymes. Biometals. 2002;15:225-235. doi: 10.1023/A:1016091118583

[19] Hubscher U, Maga G, Villani G, Spadari S. DNA Polymerases: Discovery, Characterization and Functions in Cellular DNA Transactions. Singapore: World Scientific Publishing; 2010.

[20] De Baaij JHF, Hoenderop JGJ, Bindels RJM. Magnesium in man: Implications for health and disease. Physiol Rev. 2015; 95:1-46. doi: 10.1152/physrev.00012.2014

[21] Rahm M, Hoffmann R, Ashcroft NW. Atomic and ionic radii of elements 1-96. Chemistry. 2016; 22:14625-14632. doi: 10.1002/chem.201602949

[22] Greenwood NN, Earnshaw A. Chemistry of the Elements. 2nd ed. Oxford: Butterworth-Heinemann; 1997.

[23] Fenton E. Silicon Biochemistry. Hoboken, New Jersey: Wiley-Interscience; 2001.

[24] National Institute of Standards and Technology. E-STAR Program: Electron Stopping Power Data. Available from: https://physics.nist.gov/PhysRefData/Star/Text/ESTAR.html [Last accessed on 2025 May 21].

[25] National Nuclear Data Center.Al-28 Beta Decay Data. Available from: https://www.nndc.bnl.gov/ensnds/28/Al/beta_decay.pdf [Last accessed on 2025 May 21].

[26] National Nuclear Data Center. MIRD Program. Available from: https://www.nndc.bnl.gov/nudat3/mird/ [Last accessed on 2025 May 21].

[27] Sherr CJ. Cancer cell cycles. Science. 1996; 274:1672-1677. doi: 10.1126/science.274.5293.1672

[28] Nelson DL, Cox MM. Lehninger Principles of Biochemistry. 6th ed. United States: W. H. Freeman and Company.